UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Muscle biopsy in combination with myositis-specific autoantibodies aids prediction of outcomes in juvenile dermatomyositis

Deakin, CT; Yasin, SA; Simou, S; Arnold, KA; Tansley, SL; Betteridge, ZE; McHugh, NJ; ... UK Juvenile Dermatomyositis Research Group, .; + view all (2016) Muscle biopsy in combination with myositis-specific autoantibodies aids prediction of outcomes in juvenile dermatomyositis. Arthritis & Rheumatology , 68 (11) pp. 2806-2816. 10.1002/art.39753. Green open access

[thumbnail of Deakin et al_OA_2016-Arthritis & Rheumatology.pdf]
Preview
Text
Deakin et al_OA_2016-Arthritis & Rheumatology.pdf - Published Version

Download (285kB) | Preview

Abstract

OBJECTIVE: Juvenile dermatomyositis (JDM) is a rare and severe autoimmune condition characterized by rash and proximal muscle weakness. While some patients respond to standard treatment, others do not. We investigated whether histopathology and myositis-specific autoantibodies (MSA) have prognostic significance. // METHODS: Muscle biopsy samples (n=101) from the UK JDM Cohort and Biomarker Study were stained, analyzed and scored. Autoantibodies were measured (n=90) and longitudinal clinical data were collected (median follow-up 4.9 years). Long-term treatment status was modelled using generalized estimating equations. // RESULTS: Muscle biopsy scores differed according to MSA. When effects of MSA were accounted for, increased severity of muscle pathology predicted increased risk of remaining on treatment over time: 1.48-fold higher odds (1.12-1.96, p=0.0058) for the global pathology score (hVAS) and 1.10-fold higher odds (1.01-1.21, p=0.038) for the total biopsy score for the standardized score tool. A protective effect was identified in patients with anti-Mi2 autoantibodies, who had 7.06-fold lower odds (1.41-35.36, p=0.018) of remaining on treatment, despite displaying more severe muscle pathology at biopsy. For patients with anti-NXP-2, anti-TIF1γ autoantibodies or no-detectable autoantibody, increased severity of muscle pathology alone could predict the risk of remaining on treatment, without adjustment for MSA: 1.61-fold higher odds (1.16-2.22, p=0.0040) for hVAS and 1.13-fold higher odds (1.03-1.24, p=0.013) for total biopsy score. // CONCLUSION: Muscle pathology, in combination with MSA, predicts the risk of remaining on treatment in JDM and may be useful for discussing probable treatment length with parents and patients. Understanding these associations may identify patients at greater risk of severe disease.

Type: Article
Title: Muscle biopsy in combination with myositis-specific autoantibodies aids prediction of outcomes in juvenile dermatomyositis
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/art.39753
Publisher version: http://dx.doi.org/10.1002/art.39753
Language: English
Additional information: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > ICH - Laboratory Management
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept
URI: https://discovery.ucl.ac.uk/id/eprint/1496076
Downloads since deposit
22Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item